28036301|t|ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women
28036301|a|Host immunogenetic background plays an important role in human papillomavirus (HPV) infection and cervical cancer development. Inositol 1,4,5-triphosphate receptor type 3 (ITPR3) is essential for both immune activation and cancer pathogenesis. We aim to investigate if ITPR3 genetic polymorphisms are associated with the risk of cervical cancer in Taiwanese women. ITPR3 rs3748079 A/G and rs2229634 C/T polymorphisms were genotyped in a hospital-based study of 462 women with cervical squamous cell carcinoma (CSCC) and 921 age-matched healthy control women. The presence and genotypes of HPV in CSCC was determined. No significant association of individual ITPR3 variants were found among controls, CSCC, and HPV-16 positive CSCC. However, we found a significant association of haplotype AT between CSCC and controls (OR = 2.28, 95% CI 1.31-3.97, P = 2.83 × 10-3) and the OR increased further in CSCC patients infected with HPV-16 (OR = 2.89, 95% CI 1.55-5.37, P = 4.54 × 10-4). The linkage disequilibrium analysis demonstrated that ITPR3 association with CSCC was independent of HLA-DRB1 alleles. In conclusion, these findings suggest that AT haplotype in the ITPR3 gene may serve as a potential marker for genetic susceptibility to CSCC.
28036301	0	10	ITPR3 gene	T028	C1416519
28036301	11	20	haplotype	T032	C0018591
28036301	40	72	cervical squamous cell carcinoma	T191	C0279671
28036301	73	77	risk	T078	C0035647
28036301	81	90	Taiwanese	T098	C1556096
28036301	91	96	women	T098	C0043210
28036301	97	115	Host immunogenetic	T091	C0021005
28036301	154	190	human papillomavirus (HPV) infection	T047	C0343641
28036301	195	222	cervical cancer development	T191	C1516170
28036301	224	267	Inositol 1,4,5-triphosphate receptor type 3	T028	C1416519
28036301	269	274	ITPR3	T028	C1416519
28036301	298	315	immune activation	T043	C1155000
28036301	320	326	cancer	T191	C0006826
28036301	327	339	pathogenesis	T046	C0699748
28036301	366	371	ITPR3	T028	C1416519
28036301	372	393	genetic polymorphisms	T045	C0032529
28036301	418	441	risk of cervical cancer	T081	C0596244
28036301	445	454	Taiwanese	T098	C1556096
28036301	455	460	women	T098	C0043210
28036301	462	467	ITPR3	T028	C1416519
28036301	468	481	rs3748079 A/G	T086	C0752046
28036301	486	513	rs2229634 C/T polymorphisms	T086	C0752046
28036301	519	528	genotyped	T032	C0017431
28036301	534	554	hospital-based study	T062	C2603343
28036301	562	567	women	T098	C0043210
28036301	573	605	cervical squamous cell carcinoma	T191	C0279671
28036301	607	611	CSCC	T191	C0279671
28036301	633	648	healthy control	T080	C2986479
28036301	649	654	women	T098	C0043210
28036301	673	682	genotypes	T032	C0017431
28036301	686	689	HPV	T005	C0021344
28036301	693	697	CSCC	T191	C0279671
28036301	755	760	ITPR3	T028	C1416519
28036301	761	769	variants	T028	C0678941
28036301	797	801	CSCC	T191	C0279671
28036301	807	822	HPV-16 positive	T034	C4288937
28036301	823	827	CSCC	T191	C0279671
28036301	876	888	haplotype AT	T032	C0018591
28036301	897	901	CSCC	T191	C0279671
28036301	916	918	OR	T081	C0028873
28036301	931	933	CI	T081	C0009667
28036301	970	972	OR	T081	C0028873
28036301	994	998	CSCC	T191	C0279671
28036301	999	1016	patients infected	T101	C0030705
28036301	1022	1028	HPV-16	T005	C0999806
28036301	1030	1032	OR	T081	C0028873
28036301	1045	1047	CI	T081	C0009667
28036301	1081	1112	linkage disequilibrium analysis	T063	C1517888
28036301	1131	1136	ITPR3	T028	C1416519
28036301	1137	1148	association	T063	C2717881
28036301	1154	1158	CSCC	T191	C0279671
28036301	1178	1186	HLA-DRB1	T028	C1415576
28036301	1187	1194	alleles	T028	C0002085
28036301	1239	1251	AT haplotype	T032	C0018591
28036301	1259	1269	ITPR3 gene	T028	C1416519
28036301	1285	1301	potential marker	T045	C0017393
28036301	1306	1328	genetic susceptibility	T032	C0314657
28036301	1332	1336	CSCC	T191	C0279671